Jiangsu Hengrui Signs Research Deal with MD Anderson Cancer Center

Jiangsu Hengrui Medicine signed a three-year oncology research agreement with The University of Texas MD Anderson Cancer Center. The two entities described their collaboration as a joint translational research effort, combining scientific and clinical capabilities. The goal is to develop rational combination therapies and personalized medicines with an immunotherapy focus. Hengrui is developing its own PD-1 immunotherapy and, most likely, wants to identify the best targets and treatment regimens for the asset. More details.... Stock Symbol: (SHA: 600276) Share this with colleagues: // //